WANY
TVTX icon

Wealthspire Advisors (New York)’s Travere Therapeutics TVTX Stock Holding History

Wealthspire Advisors (New York)’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-4
Closed -$96 – 2763
2025
Q3 		$96 Buy
+4
New +$75 ﹤0.01% 2996

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Wealthspire Advisors (New York)'s TVTX Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of Travere Therapeutics (TVTX) in Q4 2025, closing a stake of 4 shares — an estimated $96 sold.

Wealthspire Advisors (New York) first reported a position in TVTX in Q3 2025 and held it in 1 quarter. The position peaked at $96 in Q3 2025. 278 funds tracked by Wall St. Rank hold TVTX as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining Travere Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 4 Travere Therapeutics shares in Q4 2025, an estimated $96.
  • Wealthspire Advisors (New York) first reported a position in Travere Therapeutics in Q3 2025 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s Travere Therapeutics position peaked at $96 in Q3 2025.
  • 278 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.